Skip to content
DataLookout
Menu

INSPIRE-COPD-ENCT07275359

Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Sep 1, 2026 to Feb 1, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Primary completion pushed from Sep 1, 2028 to Feb 1, 2029
    • Study completion pushed from Oct 2, 2029 to Oct 1, 2030
    • Site contact updated
  2. Notable Primary completion pushed from Mar 31, 2027 to Sep 1, 2028
    • Study completion pushed from Sep 30, 2027 to Oct 2, 2029
    v3
  3. Notable Start date: Mar 1, 2026 to Sep 1, 2026
    • Site contact updated
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Determine feasibility of metformin administration in older persons with COPD without diabetes
Timeframe: 6 months
Determine acceptability of metformin administration in older persons with COPD without diabetes
Timeframe: 6 months
Determine safety of metformin administration in older persons with COPD without diabetes
Timeframe: 6 months
Determine tolerability of metformin administration in older persons with COPD without diabetes
Timeframe: 6 months

Arms and interventions

MetforminExperimental

Metformin in COPD patients without diabetes

Drugs: Metformin

Sites

1 site in 1 country

  • Duke Asthma, Allergy, and Airway CenterDurham, North Carolina, United States